WO2026076260A1 - Méthodes et compositions d'inhibition de mmp-9 destinées à être utilisées avec des troubles d'ossification hétérotopique non génétiques - Google Patents

Méthodes et compositions d'inhibition de mmp-9 destinées à être utilisées avec des troubles d'ossification hétérotopique non génétiques

Info

Publication number
WO2026076260A1
WO2026076260A1 PCT/US2025/049262 US2025049262W WO2026076260A1 WO 2026076260 A1 WO2026076260 A1 WO 2026076260A1 US 2025049262 W US2025049262 W US 2025049262W WO 2026076260 A1 WO2026076260 A1 WO 2026076260A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmp
antibody
dose
heterotopic
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/049262
Other languages
English (en)
Inventor
Victoria Smith
Pankaj Bhargava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ashibio Inc
Original Assignee
Ashibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashibio Inc filed Critical Ashibio Inc
Publication of WO2026076260A1 publication Critical patent/WO2026076260A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente divulgation concerne des méthodes de traitement d'ossification hétérotopique non génétique et d'autres affections à médiation par MMP. De telles méthodes visent à inhiber la MMP active ou à inhiber l'activation de MMP dans des applications thérapeutiques. De telles méthodes comprennent l'utilisation d'anticorps anti-MMP-9 dirigés contre la MMP-9. Ces méthodes évitent les effets délétères de traitement de l'ossification hétérotopique non génétique et d'autres affections médiées par MMP avec des inhibiteurs de MMP à large spectre.
PCT/US2025/049262 2024-10-03 2025-10-02 Méthodes et compositions d'inhibition de mmp-9 destinées à être utilisées avec des troubles d'ossification hétérotopique non génétiques Pending WO2026076260A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463703192P 2024-10-03 2024-10-03
US63/703,192 2024-10-03
US202563795084P 2025-04-25 2025-04-25
US63/795,084 2025-04-25

Publications (1)

Publication Number Publication Date
WO2026076260A1 true WO2026076260A1 (fr) 2026-04-09

Family

ID=97754328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/049262 Pending WO2026076260A1 (fr) 2024-10-03 2025-10-02 Méthodes et compositions d'inhibition de mmp-9 destinées à être utilisées avec des troubles d'ossification hétérotopique non génétiques

Country Status (1)

Country Link
WO (1) WO2026076260A1 (fr)

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
WO1996007399A1 (fr) 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Preparation a liberation prolongee renfermant un sel metal de peptide
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1996040072A2 (fr) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition pour la liberation soutenue d'une hormone de croissance humaine
WO1997003692A1 (fr) 1995-07-14 1997-02-06 Novo Nordisk A/S Formulation pharmaceutique stabilisee comprenant une hormone de croissance pre-traitee avec des ions zinc et facultativement lysine ou calcium
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5654010A (en) 1992-12-02 1997-08-05 Alkermes, Inc. Composition for sustained release of human growth hormone
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO2002066057A2 (fr) 2001-02-23 2002-08-29 Biophage Inc. Methodes et compositions de prevention et de traitement de maladies induites par les neutrophiles
WO2006037513A1 (fr) 2004-10-09 2006-04-13 Bayer Healthcare Ag Agents diagnostiques et agents therapeutiques utilises dans le cadre de maladies associees a la metalloproteinase 9 matricielle (mmp9)
WO2008102359A1 (fr) 2007-02-23 2008-08-28 Yeda Research And Development Co. Ltd. Anticorps et compositions pharmaceutiques contenant ces anticorps utiles pour inhiber l'activité des métalloprotéines
WO2009111508A2 (fr) 2008-03-03 2009-09-11 Dyax Corp. Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
WO2010048455A1 (fr) 2008-10-22 2010-04-29 Revalesio Corporation Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)
WO2011028883A2 (fr) 2009-09-03 2011-03-10 Dyax Corp. Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2
WO2012048291A2 (fr) 2010-10-08 2012-04-12 Proteapex Therapeutics Llc Compositions et procédés pour l'inhibition d'interactions de substrat de mmp:mmp
US20120135004A1 (en) 2010-08-27 2012-05-31 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
WO2012154654A2 (fr) 2011-05-06 2012-11-15 Baylor College Of Medicine Procédés d'imagerie de cellules osseuses précurseurs au moyen d'agents d'imagerie à double marquage, pour la détection de cellules positives mmp-9
WO2016023979A1 (fr) 2014-08-13 2016-02-18 Calypso Biotech Sa Anticorps spécifiques pour la mmp9
WO2016130897A1 (fr) 2015-02-13 2016-08-18 Yu Paul B Méthodes et compositions visant à traiter ou prévenir une formation osseuse anormale dans un tissu mou
WO2017177179A1 (fr) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
US10000562B2 (en) 2011-10-31 2018-06-19 Genentech, Inc. Antibody formulations
WO2023278491A1 (fr) 2021-06-28 2023-01-05 Releviate, Llc Anticorps anti-mmp-9 et leurs utilisations
WO2023192880A2 (fr) 2022-03-29 2023-10-05 The Trustees Of The University Of Pennsylvania Procédés de traitement, d'amélioration et/ou de prévention de la fibrodysplasie ossifiante progressive et de l'ossification hétérotopique, et kits associés
WO2025076280A1 (fr) * 2023-10-05 2025-04-10 Ashibio, Inc. Méthodes et compositions de traitement de troubles médiés par la mmp-9

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5654010A (en) 1992-12-02 1997-08-05 Alkermes, Inc. Composition for sustained release of human growth hormone
WO1996007399A1 (fr) 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Preparation a liberation prolongee renfermant un sel metal de peptide
WO1996040072A2 (fr) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition pour la liberation soutenue d'une hormone de croissance humaine
WO1997003692A1 (fr) 1995-07-14 1997-02-06 Novo Nordisk A/S Formulation pharmaceutique stabilisee comprenant une hormone de croissance pre-traitee avec des ions zinc et facultativement lysine ou calcium
WO2002066057A2 (fr) 2001-02-23 2002-08-29 Biophage Inc. Methodes et compositions de prevention et de traitement de maladies induites par les neutrophiles
WO2006037513A1 (fr) 2004-10-09 2006-04-13 Bayer Healthcare Ag Agents diagnostiques et agents therapeutiques utilises dans le cadre de maladies associees a la metalloproteinase 9 matricielle (mmp9)
WO2008102359A1 (fr) 2007-02-23 2008-08-28 Yeda Research And Development Co. Ltd. Anticorps et compositions pharmaceutiques contenant ces anticorps utiles pour inhiber l'activité des métalloprotéines
WO2009111508A2 (fr) 2008-03-03 2009-09-11 Dyax Corp. Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
WO2010048455A1 (fr) 2008-10-22 2010-04-29 Revalesio Corporation Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)
WO2011028883A2 (fr) 2009-09-03 2011-03-10 Dyax Corp. Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2
US8377443B2 (en) 2010-08-27 2013-02-19 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
US20120135004A1 (en) 2010-08-27 2012-05-31 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
WO2012048291A2 (fr) 2010-10-08 2012-04-12 Proteapex Therapeutics Llc Compositions et procédés pour l'inhibition d'interactions de substrat de mmp:mmp
WO2012154654A2 (fr) 2011-05-06 2012-11-15 Baylor College Of Medicine Procédés d'imagerie de cellules osseuses précurseurs au moyen d'agents d'imagerie à double marquage, pour la détection de cellules positives mmp-9
US10000562B2 (en) 2011-10-31 2018-06-19 Genentech, Inc. Antibody formulations
WO2016023979A1 (fr) 2014-08-13 2016-02-18 Calypso Biotech Sa Anticorps spécifiques pour la mmp9
WO2016130897A1 (fr) 2015-02-13 2016-08-18 Yu Paul B Méthodes et compositions visant à traiter ou prévenir une formation osseuse anormale dans un tissu mou
WO2017177179A1 (fr) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
WO2023278491A1 (fr) 2021-06-28 2023-01-05 Releviate, Llc Anticorps anti-mmp-9 et leurs utilisations
WO2023192880A2 (fr) 2022-03-29 2023-10-05 The Trustees Of The University Of Pennsylvania Procédés de traitement, d'amélioration et/ou de prévention de la fibrodysplasie ossifiante progressive et de l'ossification hétérotopique, et kits associés
WO2025076280A1 (fr) * 2023-10-05 2025-04-10 Ashibio, Inc. Méthodes et compositions de traitement de troubles médiés par la mmp-9

Non-Patent Citations (97)

* Cited by examiner, † Cited by third party
Title
AGARWAL ET AL.: "Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification", MOL THER, 2017
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., NUCLEIC ACIDS RES, vol. 25, 1997, pages 3389 - 3402
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
ANONYMOUS: "ashibio Reports Promising Preclinical Data for Two First-in-Class Antibodies Targeting Debilitating Bone Disorders at ASBMR Meeting - ashibio", 8 September 2025 (2025-09-08), XP093361388, Retrieved from the Internet <URL:https://ashibio.com/ashibio-reports-promising-preclinical-data-for-two-first-in-class-antibodies-targeting-debilitating-bone-disorders-at-asbmr-meeting/> *
BARBAS ET AL., PROC NAT. ACAD. SCI, vol. 91, 1994, pages 3809 - 3813
BENKE K ET AL.: "The role of transforming growth factor-beta in Marfan syndrome", CARDIOL J., vol. 20, no. 3, 2013, pages 227 - 34
BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86 - 95
CALDWELLJOYCE, PCR METHODS APPLIC, vol. 2, 1992, pages 28 - 33
CELLS, vol. 8, no. 9, September 2019 (2019-09-01), pages 984
CIONE EPIEGARI EGALLELLI G ET AL.: "Expression of MMP-2, MMP-9, and NGAL in Tissue and Serum of Patients with Vascular Aneurysms and Their Modulation by Statin Treatment: A Pilot Study", BIOMOLECULES, vol. 10, no. 3, 2020, pages 359
CLELAND: "Vaccine Design: The Subunit and Adjuvant Approach", 1995, PLENUM PRESS, article "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems", pages: 439 - 462
COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", ALAN R. LISS, 1985, pages 77
DAVIS EL ET AL., BONE, vol. 109, 2017, pages 22 - 27
DAVIS EL ET AL.: "Location-dependent heterotopic ossification in the rat model: The role of activated matrix metalloproteinase 9", J ORTHOP RES, vol. 34, no. 11, 2016, pages 1894 - 1904
DAVIS ELEANOR L. ET AL: "Location-dependent heterotopic ossification in the rat model: The role of activated matrix metalloproteinase 9", JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 34, no. 11, 14 March 2016 (2016-03-14), US, pages 1894 - 1904, XP093249376, ISSN: 0736-0266, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jor.23216> DOI: 10.1002/jor.23216 *
EVANS ET AL., J. MED. CHEM., vol. 30, 1987, pages 1229
FARINA ARMACKAY AR: "Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression", CANCERS, vol. 6, 2014, pages 240 - 296
FAUCHERE, J. ADV. DRUG RES., vol. 15, 1986, pages 29
FEDAK, P. ET AL.: "Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol. 126, no. 3, 2003, pages 797 - 805
FIESER: "Larock's Comprehensive Organic Transformations", vol. 1-17, 1989, ELSEVIER SCIENCE PUBLISHERS, pages: 91
FISHWALD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 826 - 851
GISHSTATES, NATURE GENET, vol. 3, 1993, pages 266 - 272
GOSSAGE DLAP SZHENG HXIN YLAL P ET AL.: "Phase 1b Study of the safety, pharmacokinetics, and disease-related outcomes of the matrix metalloproteinase-9 inhibitor andecaliximab in patients with rheumatoid arthritis", CLIN. THER., vol. 40, 2018, pages 156 - 65
HACKEL D ET AL.: "Transient opening of the perineurial barrier for analgesic drug delivery", PROC NATL ACAD SCI, vol. 109, 2012, pages 2018 - 2027
HANEMAAIJER, R. ET AL.: "Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells", ADVANCES IN DENTAL RESEARCH, vol. 12, 1998, pages 114 - 118
HARAN MJ ET AL.: "Pharmacological interventions for treating acute heterotopic ossification", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2004
HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038
HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896
HISATO TAKAGIHIDEAKI MANABENORIKAZU KAWAISHIN-NOSUKE GOTOTAKUYA UMEMOTO: "Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis", INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, vol. 9, no. 3, 2009, pages 437 - 440
HOLLINGER ET AL., PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 6444 - 6448
HOOGENBOOM ET AL., J. MOL. BIOL, vol. 227, 1991, pages 381
HORA ET AL., BIO/TECHNOLOGY, vol. 8, 1990, pages 755 - 758
HU JVAN DEN STEEN PEHOUDE MILENCHUK TTOPDENAKKER G: "Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody", BIOCHEM PHARMACOL, vol. 67, 2004, pages 1001 - 9
HUANG, H., SENSORS, vol. 18, no. 10, October 2018 (2018-10-01), pages 3249
HURLEGROSS, CURR. OP. BIOTECH., vol. 113, 1994, pages 428 - 433
HWANG ET AL.: "Activin A does not drive post-traumatic heterotopic ossification", BONE, 2020
IKONOMIDIS, J. ET AL.: "Effects of Deletion of the Matrix Metalloproteinase 9 Gene on Development of Murine Thoracic Aortic Aneurysms", CIRCULATION, vol. 112, 2005, pages 242 - 248
IKONOMIDIS, J. ET AL.: "Expression of Matrix Metalloproteinases and Endogenous Inhibitors Within Ascending Aortic Aneurysms of Patients With Marfan Syndrome", CIRCULATION, vol. 1-40, 2006, pages 365 - 370
JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 2004
JOHNSON ET AL., NAT. MED., vol. 2, 1996, pages 795 - 799
JOHNSSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277
JOHNSSON, B. ET AL., J. MOL. RECOGNIT., vol. 8, 1995, pages 125 - 131
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
JONES, A., ADV. DRUG DELIVERY REV., vol. 10, 1993, pages 29 - 90
JONSSON, U. ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19 - 26
JONSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627
KRIDEL S.J.CHEN E.KOTRA L.P.HOWARD E.W.MOBASHERY S.SMITH J.W.: "Substrate hydrolysis by matrix metalloproteinase-9", J. BIOL. CHEM., vol. 276, 2001, pages 20572 - 20578
LAZARD ZW ET AL.: "Osteoblasts have a neural origin in heterotopic ossification", CLIN ORTHOP RELAT RES, vol. 473, 2015, pages 2790 - 2806
LEMAIRE, S.A. ET AL.: "Matrix Metalloproteinase Levels Are Elevated in Patients with Marfan Syndrome and Chronic Descending Thoracic Aortic Dissection", JOURNAL OF SURG. RES., vol. 158, no. 2, 2010, pages 171
LEUNG ET AL., TECHNIQUE, vol. 1, 1989, pages 11 - 15
LI, T.JIANG, B.LI, X. ET AL.: "Serum matrix metalloproteinase-9 is a valuable biomarker for identification of abdominal and thoracic aortic aneurysm: a case-control study", BMC CARDIOVASC DISORD, vol. 18, 2018, pages 202
LONBERG ET AL., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93
LONBERG ET AL., NATURE, vol. 368, 1994, pages 812 - 813
LOUNEV VITALI ET AL: "Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice", JOURNAL OF BONE AND MINERAL RESERCH, vol. 39, no. 4, 16 February 2024 (2024-02-16), pages 382 - 398, XP093249142, ISSN: 1523-4681, Retrieved from the Internet <URL:http://www.jbmr.org/view/0/journalIssues.html> DOI: 10.1093/jbmr/zjae029 *
MADDEN ET AL., METH. ENZYMOL., vol. 266, 1996, pages 131 - 141
MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581
MARSHALLDEREK C ET AL.: "Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer", PLOS ONE, vol. 10, no. 5, 11 May 2015 (2015-05-11), pages 0127063
MARTENS ELEYSSEN AVAN AELST 1FITEN PPICCARD HHU J ET AL.: "A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains", BIOCHIM BIOPHYS ACTA, vol. 1770, 2007, pages 178 - 86
MEYERS C ET AL.: "Heterotopic Ossification: A Comprehensive Review", JBMR PLUS, vol. 3, no. 4, 2019, pages 10172
ORTEGA N ET AL.: "Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation", DIS MODEL MECH, vol. 3, no. 3-4, 2010, pages 224 - 35
ORTEGA N ET AL.: "Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation", DISEASE MODELS & MECHANISMS, vol. 3, 2010, pages 224 - 235
PAEMEN LMARTENS EMASURE SOPDENAKKER G: "Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity", EUR J BIOCHEM, vol. 234, 1995, pages 759 - 65
PEARSON, METHODS ENZYMOL, vol. 183, 1990, pages 63 - 98
PEARSON, METHODS MOL. BIOL., vol. 24, 1994, pages 307 - 31
PETERSON ET AL.: "Direct Mouse Trauma/Burn Model of Heterotopic Ossification", J. VIS. EXP, 2015
PETERSON JR ET AL., J. VIS. EXP., vol. 102, 2015, pages 52880
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
RAMELLA M ET AL.: "Endothelial MMP-9 drives the inflammatory response in abdominal aortic aneurysm (AAA", AM J TRANSL RES, vol. 9, no. 12, 2017, pages 5485 - 5495
RANGANATHAN K ET AL., J BONE JOINT SURG AM, vol. 97, no. 17, 2015
RANGANATHAN, K.LODER, S.AGARWAL, S.WONG, V.W.FORSBERG, J.DAVID, T.A.WANG, S.JAMES, A.W.LEVI, B., J BONE JOINT SURG AM, vol. 97, no. 13, 1 July 2015 (2015-07-01), pages 1101 - 1111
REIDHAAR-OLSONSAUER, SCIENCE, vol. 241, 1988, pages 53 - 57
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
RODENBERG E ET AL.: "Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model", TISSUE ENG PART A, vol. 17, 2011, pages 2487 - 2496
SALISBURY E ET AL.: "Sensory nerve induced inflammation contributes to heterotopic ossification", J CELL BIOCHEM, vol. 112, no. 2748-2758, 2011, pages 2748 - 2758
SANDBOM WJBHANDARI BRRANDALL CYOUNES ZHROMANCZYK TXIN Y ET AL.: "Andecaliximab [anti-matrix metalloproteinase-9] induction therapy for ulcerative colitis: a randomised, double-blind, placebo-controlled, phase 2/3 study in patients with moderate to severe disease", J CROHNS COLITIS, vol. 12, 2018, pages 1021 - 9
SANDBORN WJBHANDARI BRFOGEL RONKEN JYEN EZHAO X ET AL.: "Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis", ALIMENT PHARMACOL THER, vol. 44, 2016, pages 157 - 69
SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155
SEGURA AM ET AL.: "Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome", CIRCULATION, vol. 98, no. II, 1998, pages 331 - 7
SELA-PASSWELL NKIKKERI RDYM OROZENBERG HMARGALIT RARAD-YELLIN R ET AL.: "Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential", NAT MED, vol. 18, 2011, pages 143 - 7
SHIMONO KTUNG WEMACOLINO CCHI AHDIDIZIAN JHMUNDY CCHANDRARATNA RAMISHINA YENOMOTO-IWAMOTO MPACIFICI M: "Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-y agonists", NAT MED, vol. 17, no. 4, 3 April 2011 (2011-04-03), pages 454 - 60
SHIMONO KTUNG WEMACOLINO CCHI AHDIDIZIAN JHMUNDY CCHANDRARATNA RAMISHINA YENOMOTO-IWAMOTO MPACIFICI M: "Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists", NAT MED, vol. 17, no. 4, 3 April 2011 (2011-04-03), pages 454 - 60
SHIMONO KTUNG WEMACOLINO CCHI AHDIDIZIAN JHMUNDY CCHANDRARATNA RAMISHINA YENOMOTO-IWAMOTO MPACIFICI M: "Potent inhibition of osteochondromas, osteosarcomas and hereditary multiple exostoses by nuclear retinoic acid receptor-γ agonists", NAT MED, vol. 17, no. 4, 3 April 2011 (2011-04-03), pages 454 - 60
SMITH V ET AL: "Presentation SAT-290: MMP9 deficiency protects against trauma-induced heterotopic ossification", ASBMMR 2005, 5 September 2025 (2025-09-05), XP093361643, Retrieved from the Internet <URL:https://ashibio.com/wp-content/uploads/2025/09/ASBMR_2025-BT-20250730_draft_v1.pdf> *
STRONG ET AL.: "BMP Ligand Trap ALK3-Fc Attenuates Osteogenesis and Heterotopic Ossification in Blast-Related Lower Extremity Trauma", STEM CELLS DEV, 2021
TAYLOR, L. D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295
TOWLER, D.: "Molecular and Cellular Aspects of Calcific Aortic Valve Disease", CIRC. RES., vol. 113, no. 2, 2013, pages 198 - 208
TSUI FWL ET AL.: "The role of LCN2 and LCN2-MMP9 in spondylitis radiographic development: gender and HLA-B27 status differences", ARTHRITIS RESEARCH & THERAPY, vol. 24, 2022, pages 164
VANDOOREN J.VAN DEN STEEN P.E.OPDENAKKER G.: "Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade", CRIT. REV. BIOCHEM. MOL. BIOL., vol. 48, 2013, pages 222 - 272
VASWANIHAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL, vol. 1, 1998, pages 105 - 115
VEBERFREIDINGER, TRENDS NEUROSCI, vol. 8, 1985, pages 392 - 396
WENKERT DEBORAH ET AL: "Inhibition of MMP9 as a novel treatment strategy for Fibrodysplasia Ossificans Progressiva (FOP): Safety analysis of the anti-MMP9 antibody Andecaliximab in development for FOP", ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-BONE-AND-MINERAL-RESEARCH (ASBMR) TORONTO, CANADA, 28 September 2024 (2024-09-28), XP093361317, Retrieved from the Internet <URL:https://asbmr.confex.com/asbmr/2024/meetingapp.cgi/Paper/3125> *
YABLUCHANSKIY, A.MA, Y.IYER, R.P.HALL, M.E.LINDSEY, M. L., PHYSIOLOGY, vol. 28, no. 6, November 2013 (2013-11-01), pages 391 - 403
YASUDA ET AL., BIOMED. THER., vol. 27, 1993, pages 1221 - 1223
ZAPATA ET AL., PROTEIN ENG, vol. 8, no. 10, 1995, pages 1057 - 1062
ZHANGMADDEN, GENOME RES, vol. 7, 1997, pages 649 - 656

Similar Documents

Publication Publication Date Title
JP7794630B2 (ja) ＴＧＦβ１結合性免疫グロブリンおよびその使用
AU2020294193B2 (en) Anti-pro/latent-Myostatin antibodies and uses thereof
US11439704B2 (en) Methods for using anti-myostatin antibodies
US20190209682A1 (en) Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
ES2978990T3 (es) Métodos de reducción del riesgo cardiovascular
US9969806B2 (en) Administration of bimagrumab for improving muscle mass and function after hip fracture surgery
JP6560341B2 (ja) 進行性骨化性線維異形成症の治療
US20190218283A1 (en) Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
BR112020016401A2 (pt) Uso de anticorpos anti-il-36r para o tratamento de doença inflamatória intestinal
JP2016508504A (ja) 対象に対する抗アクチビン−ａ化合物の投与
US12421321B2 (en) Methods for treating fibrodysplasia ossificans progressiva
KR20170045240A (ko) 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
WO2026076260A1 (fr) Méthodes et compositions d&#39;inhibition de mmp-9 destinées à être utilisées avec des troubles d&#39;ossification hétérotopique non génétiques
JP2024541933A (ja) 抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法
US20240002491A1 (en) Methods for selecting patients for treatment with an ngf antagonist
WO2026022216A1 (fr) Utilisations d&#39;anticorps anti-cd127 dans le traitement de maladies intestinales inflammatoires
EA050977B1 (ru) Способ снижения или предупреждения образования новых поражений с гетеротопической оссификацией у субъектов с прогрессирующей оссифицирующей фибродисплазией (fop)
HK40089584A (en) Tgfbeta1-binding immunoglobulins and use thereof
HK1260186A1 (en) Tgfbeta1-binding immunoglobulins and use thereof
HK1260186B (en) Tgfbeta1-binding immunoglobulins and use thereof
EA045920B1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека